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S U M M A R Y
Background: The gold standard treatment for chronic hepatitis C virus (HCV) infection is pegylated
interferon (PEG-IFN) in combination with ribavirin. Most patients treated with PEG-IFN achieve a
sustained virological response (SVR). However host genetic factors play a vital role in the spontaneous
and treatment-induced clearance of HCV infection from these infected patients. In the current study,
polymorphisms of IL28B (rs8099917 and rs12979860) were analyzed and their association with the
virological response to PEG-IFN alpha treatment was determined.
Methods: One hundred and ﬁfty HCV genotype 3 patients were assessed to study the correlation of IL28B
with a therapeutic regimen of PEG-IFN alpha plus ribavirin. Twenty patients were excluded due to a
refusal to participate in the study and 25 patients failed to meet the inclusion criteria. Of the 105 patients
recruited, 49 (46.7%) were male and 56 (53.3%) were female. In order to determine single nucleotide
polymorphisms of rs8099917 and rs12979860, the sample was ampliﬁed by PCR and then IL28B typing
was carried out by restriction fragment length polymorphism (RFLP) followed by standard sequencing.
Results: We found three types of genotype in rs8099917 of IL28B: wild-type TT in 60.0% of patients,
heterozygous GT minor genotype in 36.2%, and GG in 3.8%. The frequency of the CC genotype of
rs12979860 was 54.3%, CT was 37.1%, and TT was 8.6%. Overall, SVR was achieved in 68.6% of patients. A
higher SVR was achieved for patients with the favorable genotype CC of rs12979860, with 84.2% as
compared to 56.4% and 22.2% for minor genotype CT and TT, respectively (p = 0.0001). We did not ﬁnd a
signiﬁcant association for SVR to antiviral treatment in patients with genotype TT (rs8099917) (71.9%,
p = 0.36). The rapid virological response (RVR) rate was signiﬁcantly higher in patients with major
genotype TT (88.9%, p = 0.04). These results show that IL28B polymorphism is highly associated with SVR
to therapy in the Pakistani population infected with HCV genotype 3.
Conclusions: HCV-infected patients carrying homozygous C/C have a higher chance of SVR. In addition,
patients who carry T/T (rs8099917) have a higher chance of RVR.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Infection with the hepatitis C virus (HCV) is a major cause of
chronic liver disease, which in turn may lead to the development of
cirrhosis and hepatocellular carcinoma (HCC). Cytokines are natural
barriers to different viral infections. The human body is capable of* Corresponding author. Tel.: +91 92 3004852451.
E-mail address: hafsa.aziz@gmail.com (H. Aziz).
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).producing cytokines differently depending on genetic makeup or
polymorphism of the cytokine production genes; this polymor-
phism affects cytokine production and thus the immune response.
Several antiviral treatments are in the process of authorization.
However, the gold standard treatment for chronic HCV infection
remains pegylated interferon (PEG-IFN) in combination with
ribavirin. Nevertheless, some patients treated with PEG-IFN do
not achieve a sustained virological response (SVR) and experience
side effects. Moreover it is expensive. Therefore it is important to
identify the factors that affect the response to treatment.1–3ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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treatment-induced clearance of HCV infection from infected
patients. Recently, genome-wide association studies have identi-
ﬁed a single nucleotide polymorphism (SNP) near the IL28B gene
on chromosomes 19 that encodes interferon lambda 3 (IFN-l3),4
which is considered to be strongly effective against HCV. It is
associated with treatment-induced and spontaneous clearance of
HCV from infected patients and predicts the response to the
antiviral therapy. Several studies have reported that genetic
variants of the IL28B gene behave differently to treatment and may
be useful to identify a patient’s likelihood of response to PEG-IFN
treatment.5–7 Recently Suppiah et al.8 reported an association
between the SNP rs8099917 and SVR. In another study, Tanaka
et al. also reported the importance of SNP rs8099917 in terms of
treatment response and found the presence of a G allele to be
associated with a signiﬁcantly lower SVR (0% for genotype GG and
78% for genotype TT).5
The aim of this study was to investigate the association of SNPs
rs8099917 and rs12979860 (IL28B gene) to the response to
treatment in HCV genotype 3 patients in Pakistan.
2. Materials and methods
2.1. Patient selection
This study was conducted at the Nuclear Medicine, Oncology
and Radiotherapy Institute and Maroof International Hospital from
May 2011 to June 2013. The study was approved by the ethics
review committees of both hospitals, and patient consent was
obtained from all patients enrolled in the study.
One hundred and ﬁfty patients who had been HCV RNA carriers
for more than 6 months were screened. Their alanine aminotrans-
ferase (ALT) levels had increased to twice the upper limit of the
normal range. For inclusion, patients had to have HCV genotype 3,
be aged >16 years, male or female, and negative for hepatitis B
virus (HBV). Those who fulﬁlled the study criteria were placed on
antiviral therapy. Therapy was started with PEG-IFN alpha-2a
180 mg weekly and 400 mg of ribavirin twice daily. Blood samples
from these subjects were collected in ethylenediaminetetraacetic
acid (EDTA)-containing tubes, which were stored at 80 8C.
2.2. Study design
Patients were evaluated to determine whether they were a
responder, non-responder, or sustained responder to treatment.
The aim of this study was to assess associations of rs8099917 and
rs12979860 genotypes with the response to treatment. A rapid
virological response (RVR) was deﬁned as undetectable HCV RNA
at the 4th week of treatment. SVR was deﬁned as undetectable HCV
RNA at 6 months after the end of treatment. Non-responders were
those who had a less than 2 log decline in HCV RNA at week 12 of
treatment. Patient relapse was deﬁned as the reappearance of HCV
RNA during the follow-up period in patients who had achieved
negative HCV RNA at the end of treatment.
Genotyping of all selected serum samples was done using a
speciﬁc genotyping assay with some modiﬁcations.9,10 The COBAS
AmpliPrep/COBAS TaqMan 48 System was used to assess HCV RNA
levels (lower limit of detection 15 IU/ml) at baseline, after 4 weeks
(RVR) and after 12 weeks of treatment, at the end of treatment
(ETR), and at 24 weeks after the end of treatment (SVR).
2.3. Restriction fragment length polymorphism (RFLP) of the ampliﬁed
product of IL28B
Genomic DNA was extracted from whole blood by phenol/
chloroform method. Ampliﬁcation of 401 bp of the IL28B gene wascarried out using primers sense 50-TTC ACC ATC CTC CTC TCA TCC
CTC AT-30 and antisense 50-TCC TAA ATT GAC GGG CCA TCT GTT TC-
30 for rs8099917 genotype detection, as reported by Moreira et al.11
The ampliﬁed product was then analyzed on 2% agarose gel. RFLP
of the ampliﬁed 401-bp product was performed by digestion with
BseMI (BsrDI) enzyme to differentiate IL28B genotypes of
rs8099917 into TT, TG and GG. The restriction pattern of IL28B
genotype was analyzed on 2% agarose gel. Gel electrophoresis
showed bands of different sizes.
For rs12979860 genotype identiﬁcation, a 694-bp product was
ampliﬁed using primers sense 50-AGCAGGACAGATTGGCAAAG-30
and antisense 50-CACAATTCCCACCCACCACGAGAC-30. The ampliﬁed
product was digested with Hpy166II and analyzed on 2% agarose gel.
2.4. Partial sequencing of the IL28B region
The IL28B region was ampliﬁed using the sense and antisense
primer pairs described above. A 50-ml reaction mixture contained
25 ml of GoTaq Green (Promega), 1.25 pmol of each primer, and
5 ml of extracted DNA. Prior to ampliﬁcation, desaturation was
done at 94 8C for 5 min, followed by 35 cycles of 60 s at 95 8C, 45 s
at 58 8C, and 60 s at 72 8C using an ABI GeneAmp 9700 (Applied
Biosystems, USA). The ampliﬁed product was analyzed on 2%
agarose gel using the Gel Doc XR System (Bio-Rad, USA). Fragment
sizes were compared with a 100-bp ladder (Fermentas). The
product was eluted using the Gene JET Gel Extraction Kit
(Fermentas). After puriﬁcation, these samples were subjected to
sequencing using an ABI Automated Sequencer (Applied Biosys-
tems). Chromas version 2.0 was used to analyze nucleotide
sequences and electropherograms of each sample. Sequences were
aligned using CLC Workbench software (http://www.clcbio.com).
2.5. Statistical analysis
SPSS v. 15.0 software (SPSS Inc., Chicago, IL, USA) was used for
the data analysis. Categorical variables are given as the number
and percentage. Pearson’s Chi-square test was used to estimate the
signiﬁcance of differences between categorical variables. A p-value
below 0.05 was considered signiﬁcant. Univariate and multivariate
logistic regression analysis was applied to identify factors with the
potential to predict the therapeutic outcome.
3. Results
3.1. Study enrollment and patient characteristics
One hundred and ﬁfty patients were enrolled in the study to
determine the correlation of IL28B with the response to treatment
with a regimen of PEG-IFN alpha plus ribavirin. Twenty patients
were excluded from the study due to their refusal to participate. A
further 25 patients failed to meet the inclusion criteria. Of the
105 remaining patients, 49 were male and 56 were female. Eligible
patients who met the inclusion criteria had detectable HCV RNA in
the serum, were positive for HCV antibodies by ELISA, and had HCV
genotype 3. All had a platelet count <180  109/L, white blood cell
count <4.5  109/L, and hemoglobin <12 g/dL. Patients co-infected
with HBV or any other viral diseases were excluded from the study.
The mean age of the study participants was 41.2  13. 5 years. The
major mode of acquiring HCV was dental treatment or surgery,
although most patients were unaware of the cause of infection. Table 1
summarizes the baseline characteristics of the HCV patients.
3.2. Frequencies of IL28B genotypes in HCV genotype 3 patients
Figures 1 and 2 present the electrophoresis pattern of the
restriction of IL28B (rs8099917 and rs2979860).
Table 1
Variables associated with SVR in HCV patients treated with PEG-IFN alpha 2a plus
ribavirin therapy
Variables Total number of
treated patients
SVR rate p-Value
Age, years
40 45 36 (80.0%) 0.02
>40 60 36 (60.0%)
Sex
Male 49 35 (71.4%) 0.55
Female 56 37 (66.1%)
Viral load
 8  105 IU/ml 32 24 (75.0%) 0.05
>8  105 IU/ml 73 50 (68.5%)
ALT
Normal 31 18 (58.0%) 0.08
Raised 74 50 (67.5%)
Response rate at week 4
RVR 69 54 (78.3%) 0.003
Non-RVR 36 18 (50.0%)
rs8099917
TT 64 46 (71.9%) 0.36
Non-TT (TG and GG) 41 22 (63.4%)
rs12979860
CC 58 48 (84.5%) 0.0001
Non-CC (CT and TT) 47 20 (48.9%)
SVR, sustained virological response; HCV, hepatitis C virus; PEG-IFN, pegylated
interferon; ALT, alanine aminotransferase; RVR, rapid virological response.
Figure 1. RFLP of the ampliﬁed product of rs8099917 digested with BseMI (BsrDI)
enzyme: lane 1, 50-bp DNA ladder; lane 2, positive control; lanes 3–5, genotype TT;
lanes 9–13, genotype TG; lanes 7 and 8, genotype GG.
Figure 2. RFLP of the ampliﬁed product of rs12979860: lane 1, 100-bp DNA ladder;
lanes 2 and 9, the electrophoresis pattern of genotype CT digested with Hpy166II
enzyme; lane 4, restricted PCR product of genotype TT; lanes 3 and 5–8, restricted
PCR product of genotype CC.
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alignment and comparison suggested that most of the sequences
were conserved in the ampliﬁed partial sequence of the IL28B gene.
However, there was variation at a particular position for
rs8099917, as illustrated in the nucleotide alignment in
Figure 3a. Some patients had the GG polymorphism, with position
24 occupied by G in both strands. Some patients had a T residue in
one strand and a G residue in the other strand at position 24 and
were heterozygous for the G/T polymorphism (Figures 3a and 4a).
Patients with the TT polymorphism had T in both strands of DNA.
Nucleotide alignment in Figure 3b shows the nucleotide
variation of rs12979860. For the primary genotype (CC) of
rs12979860 there is C in both strands, and in the C/T genotype
there is one strand with the C nucleotide and the other with T at the
same position in its reverse complimentary sequence (Figure 4b).All of the samples were genotyped for rs12979860 and
rs8099917. Figures 5 and 6 show the frequencies of rs8099917
genotypes and rs12979860 genotypes, respectively, in HCV-
infected patients. Genotype TT of rs8099917 was found in the
majority of patients, while genotypes TG and GG were found in a
limited number of patients. Sixty-three patients (60.0%) had the
homozygous TT polymorphism, 38 (36.2%) heterozygous TG, and
four (3.8%) homozygous GG (Figure 5). A higher frequency of CC
genotype of rs12979860 was found (57, 54.3%) as compared to CT
(39, 37.1%) and TT (9, 8.6%) genotypes (Figure 6).
3.3. Allelic frequency and response to antiviral therapy
Of 105 participants, 69 (65.7%) achieved RVR, while 36 (34.3%)
did not attain RVR (Table 1). Overall, SVR was achieved in 72
(68.6%) patients. With respect to rs8099917 genotypes, the rate of
RVR was signiﬁcantly higher in patients with major genotype TT as
compared to genotype TG (88.9% vs. 34.2%; p = 0.04), and none of
the patients with GG genotype achieved RVR. In addition, the SVR
rate in patients with genotype TT was 71.4%, with genotype TG was
65.8%, and with genotype GG was 50.0% (Figure 5). The observed
difference in SVR was non-signiﬁcant (p = 0.36; Table 1).
The rate of RVR with respect to genetic variation in rs12979860
was also analyzed and it was found that 86% of CC genotype
patients, 43.6% of CT genotype patients, and 33.3% of TT genotype
patients achieved RVR. The rate of SVR to antiviral therapy was
higher among patients with the CC genotype (84.2%) compared to
the CT (56.4%) and TT (22.2%) genotypes (Figure 6). Moreover an
association was found between the rs12979860 genotype and
treatment response in this HCV-infected cohort from the Pakistani
population. Statistical analysis showed the genotypes of
rs12979860 to be signiﬁcantly associated with the virological
response to PEG-IFN plus ribavirin therapy (p = 0.0001; Table 1).
3.4. Predictors of a sustained response
In this study we also compared host and viral factors that could
be associated with the response to the therapeutic regimen.
Preliminary analyses showed a non-signiﬁcant difference in SVR
between males and females (71.4% vs. 66.1%; p = 0.55) and
between patients with a low viral load (8  105 IU/ml) and high
viral load (>8  105 IU/ml) (68.5% vs. 68.8%; p = 0.9). We did not
observe a signiﬁcant difference in SVR between the normal ALT
group and raised ALT group. However a signiﬁcant difference in
SVR was found between patients aged 40 years (80.0%) and
patients aged >40 years (60.0%) (p = 0.02). Those who attained RVR
Figure 3. (a) Nucleotide sequence alignment showing rs8099917 polymorphisms. (b) Nucleotide sequence alignment showing rs12979860 polymorphisms. Sequences were
aligned using CLC Workbench software (http://www.clcbio.com).
Figure 4. (a) Chromatogram showing heterozygous G/T genotype. (b) Chromatogram
showing heterozygous C/T genotype.
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compared to those who did not attain RVR (50.0%) (p = 0.003). The
TT genotype of rs8099917 (IL28B) showed a non-signiﬁcant
difference in SVR as compared to the non-TT genotypes (71.9%
vs. 63.4%; p = 0.06), as shown in Table 1. However, the CC genotype
of rs12979860 had a higher SVR (84.5%) as compared to the non-CC
genotypes (48.9%) (p = 0.0001).
Univariate logistic regression analysis showed that there was
no signiﬁcant difference in SVR between male and female patients
(odds ratio (OR) 0.77, 95% conﬁdence interval (CI) 0.33–1.77; p = 0.
55), or between those with viral loads 8  105 IU/ml and
>8  105 IU/ml (OR 1.0, 95% CI 0.0.41–2.47; p = 0.9) (Figure 7).
Those aged 40 years had a 2.4 times higher SVR than patients
aged >40 years (OR 2.6, 95% CI 1.0–6.52; p = 0.03). Patients with
RVR had a ﬁve times higher SVR than those who did not achieve
RVR (OR 3.6, 95% CI 1.5–8.5; p < 0.004). Patients with the CC
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was a non-signiﬁcant difference in SVR between patients with the
TT genotype and non-TT genotypes (rs8099917) (OR 1.4, 95% CI
0.6–3.4; p = 0.3).
Multivariate logistic regression analysis was done to identify
factors that contribute signiﬁcantly to the prediction of the
therapeutic outcome. According to this analysis the CC genotype of
rs12979860 (IL28B) (CC vs. non-CC: OR 2.8, 95% CI 1.10–7.5;
p = 0.03) and RVR at week 4 (RVR vs. non-RVR: OR 3.2, 95% CI 3.28–
1.22; p = 0.01) were associated with SVR and were observed to be
signiﬁcant predictors of SVR.Figure 7. Univariate logistic regression model for the prediction of sustained virological r
using GraphPad prism software.4. Discussion
The standard treatment strategy for HCV infection with HCV
genotype 3 is combined PEG-IFN alpha and ribavirin for
24 weeks.12,13 The response to treatment is not uniform in the
HCV-infected population. It depends on several viral and host
factors, including viral load, viral genotype, age, sex, body mass
index, ethnicity, co-infections, and host genome.14,15 To date many
studies have suggested that SNPs rs8099917and rs12979860 of the
IL28B gene located on chromosome 19 are associated with SVR.5,16
IFN- l3 expressed by the IL28B gene has antiviral activity.17 In theesponse (SVR). Results are presented as the odds ratio with 95% conﬁdence interval,
H. Aziz et al. / International Journal of Infectious Diseases 30 (2015) 91–9796current study, the association of SNPs rs8099917 and rs12979860
in the IFN-l3 gene was studied with the response to PEG-IFN alpha
in Pakistani patients infected with HCV genotype 3. RFLP and
sequencing were used and both methods showed 100% sensitivity
and speciﬁcity.
Figures 5 and 6 show the three rs8099917and three rs12979860
genotypes in HCV-infected patients. The predominant genotype TT
of rs8099917 was found in 63 patients (60%), TG in 38 (36.2%), and
GG in four (3.8%). The observed frequencies in our patient
population differ from those reported previously, e.g., 70% for
TT, 29% for TG, and 1.4% for GG in a Japanese population.18 Another
study reported 86.2% TT genotype and 12.3% GT in a Korean
population.19 Ezzikouri et al.20 reported 80% for TT and 20% for GT
in Moroccan patients. With regard to rs12979860 we found a
higher frequency of CC (54.30%) than CT (37%) and TT (8.6%). Other
studies have also reported CC to be the predominant genotype in
their population.21 This ﬁnding is, however, different to that
reported by Sarrazine et al. CC 61.1%, CT 34.7%, and TT 4.2%.22
Overall, SVR was achieved in 72 patients (68.6%). The
preliminary analysis showed a non-signiﬁcant difference in SVR
between males and females (71.4% vs. 66.1%; p = 0.55). Further-
more, multivariate logistic regression analysis showed that gender
was not signiﬁcantly correlated with SVR. Our study demonstrated
a signiﬁcant difference in SVR between patients aged 40 years
(80.0%) and patients aged >40 years (60.0%) (p = 0.02). A clear
relationship between baseline viral levels and the response to
therapy was also observed. The frequency of SVR markedly
decreased as baseline viral load increased in these HCV patients
(75.0% vs. 68.5%); this has also been reported by several others.2,23
In our study we found a high SVR among patients who achieved
RVR (78.3%) (Table 1). Moreover we found higher SVR among
patients who achieved RVR (78.3%) as compared to patients who
did not achieve RVR (50%). This ﬁnding is in agreement with those
of previous studies that have reported a higher SVR among HCV
patients who achieve RVR.24,25 Other studies have also reported
higher SVR in patients who have achieved RVR regardless of any
genotype.26
Many reports have suggested that genotypes of rs12979860 are
correlated with the virological response. The present study showed
that the frequency of RVR was higher in patients with CC (86%)
than CT (43.6%) and TT (33.3%) genotypes. RVR was found to be
higher in patients with the CC genotype as compared to CT and TT
genotypes. Other studies have also found a higher antiviral
response at week 2 and week 4 of treatment.27 In contrast to
other studies, we did not ﬁnd a difference in viral load at baseline
with CC, CT, and TT genotypes. However, we found patients with
the CC genotype to have a better response (84.2%) to PEG-IFN plus
ribavirin therapy than CT (56.4%) and TT (22.2%) genotype patients.
This ﬁnding is similar to that of Sarrazin et al.,22 who reported
45.9% prevalence of the CC genotype of rs12979860 in SVR patients
and that it may be used as a prognostic factor for the antiviral
response to PEG-IFN therapy. Other studies have also conﬁrmed
this association and have reported that a low rate of SVR may be
inﬂuenced by a lower frequency of CC genotype.7,16
Based on our analysis, we observed a signiﬁcant association of
RVR with antiviral treatment in patients with the rs8099917 TT
genotype (88.9%). This observation is in line with Yu et al.,24 who
reported a high rate of RVR (85.2%) in patients who had the TT
genotype (rs8099917) as compared to patients who had non-TT
genotypes (72.0%). However we did not ﬁnd a signiﬁcant
association of SVR with antiviral treatment in patients with the
TT genotype (71.9%; p = 0.36). This ﬁnding is similar to that of Lyoo
et al.19 Another study has reported rs8099917 to be a weak
predictor of SVR in African-American patients.6
In conclusion, in HCV genotype 3 patients, rs12979860
could be a marker for predicting the outcome of antiviraltherapy. HCV-infected patients carrying homozygous CC have a
higher chance of SVR. In addition, patients carrying TT
(rs8099917) have a higher chance of RVR. A signiﬁcant genetic
correlation helps in the prediction of the response to treatment
and may lead the way to new management strategies in terms of
shorter treatment, which will ultimately reduce the costs and
side effects of therapy.
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